Urs Weber MD
@urswebermd
Proud 🇩🇪, grew up in 🇩🇪/🇨🇭/🇬🇧/🇪🇸, now living in 🇺🇸. @CUHemeOnc fellow. Views are my own.
ID: 1324756591342735360
06-11-2020 16:52:49
999 Tweet
619 Followers
330 Following
Dr. David R. Spigel, MD, FASCO presents Phase III ADRIATIC study at #ASCO24: consolidation durvalumab x 2y after chemoradiation for limited stage #SCLC. Balanced arms. >50% with PCI. Mostly daily radiation delivered.
Just donated blood with American Red Cross of Colorado and Wyoming. They’re still in the Bruce Schroffel Conference Center and are taking walk-ins. If you’re at UCH and are able you should donate!
How refreshing to take a break and enjoy the company of the fabulous CU Cancer Center lung cancer team at #WCLC24. The jokes and pasta were on point!
We are pleased to share this article out today in Cancer Discovery on the preclinical development and proof-of-concept clinical activity of NVL-655 ✅4th-generation, #ALK-selective TKI ✅CNS-penetrant ✅Broad coverage of ALK fusions and mutations, including lorlatinib-refractory compound
🌟And here with the efficacy and safety data of #NVL655, ALK-selective, TRK-sparing and brain-penetrant 4G ALK TKI, from ALKOVE-1, presented today #ESMO24 by Alexander Drilon MD ✅ ORR 38% in heavily pretreated pts overall (1-5 prior ALK TKIs) ✅ ORR 35% in pts post-lorlatinib (in which
We are excited to share the updated efficacy&safety data of #Zidesamtinib (NVL-520), a next-generation ROS1-selective, TRK-sparing, brain-penetrant inhibitor in ROS1 fusion+ solid tumors, from the ongoing #ARROS1 global phase 1/2 trial, presented today #ESMO24 by Benjamin Besse